• Merck initiated the Phase 3 ENHANCE-3 trial of Ohtuvayre to prevent COPD exacerbations in adults receiving standard care.
• The study targets approximately 2,136 patients across 28 countries with a history of exacerbations; enrollment has begun in the United States.
• Participants will receive Ohtuvayre or placebo alongside standard care to assess whether treatment reduces moderate or severe exacerbations over 52 weeks.
• Results will be shared with regulators globally.
• Ohtuvayre received FDA approval for adult COPD maintenance treatment in June 2024 following earlier trials demonstrating clinically meaningful improvements in lung function.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103140801) on November 03, 2026, and is solely responsible for the information contained therein.